Business
OKYO Pharma raises USD 20m in underwritten public offering
UK-based OKYO Pharma Limited (Nasdaq: OKYO) announced the pricing of an underwritten public offering of ordinary shares for gross proceeds of approximately...
Theriva Biologics out-licenses SYN-020 to Rasayana Therapeutics in USD 38.3m worldwide deal
Theriva Biologics (NYSE American: TOVX), a clinical-stage company headquartered in Rockville, Maryland, announced an exclusive worldwide SYN-020 license...
Lyell Immunopharma raises USD 50m in additional equity private placement tranche
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage cell therapy company based in South San Francisco, California, announced the closing of an...
Rapport Therapeutics licenses RAP-219 to Tenacia Biotechnology in USD 328m. Greater China deal
Rapport Therapeutics Licenses RAP-219 to Tenacia Biotechnology for Greater China Development and Commercialization
Insilico Medicine and Lilly sign USD 2.75b multi-target AI drug discovery collaboration
Insilico Medicine's Pharma.AI platform is the centerpiece of a new multi-program drug discovery collaboration with Eli Lilly and Company (NYSE: LLY) that...
Merck Acquires Terns Pharmaceuticals for USD 6.7b to Boost Hematology Pipeline With CML Drug
Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage oncology company, for USD 53.00...
Acumen Pharmaceuticals raises USD 35.75m in private placement
Acumen Pharmaceuticals (Nasdaq: ABOS), a U.S.-based clinical-stage biopharmaceutical company, announced a private placement of approximately USD 35.75...
Azenta and Frontier Space Partner on $X Million Space Life Sciences Research Mission
Burlington, MA and London, UK - Azenta Life Sciences (Nasdaq: AZTA) and Frontier Space have announced a groundbreaking strategic partnership aimed at...
Reviva Pharmaceuticals raises USD 10m in public offering
Cupertino, California-based Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced the closing of a public offering raising approximately USD 10...
GSK licences linerixibat worldwide rights to Alfasigma in deal worth up to USD 690m.
GSK plc (LSE/NYSE: GSK), headquartered in London, and Bologna-based Alfasigma S.p.A. have entered into a licence agreement under which Alfasigma will...
Jacobio receives USD 100m upfront from AstraZeneca for pan-KRAS inhibitor JAB-23E73 license deal
Jacobio Pharma confirmed receipt of a USD 100 million upfront payment from AstraZeneca under the license and collaboration agreement for JAB-23E73, a...
Insilico Medicine and Tenacia Biotechnology expand AI-driven CNS collaboration worth up to USD 94.75m
Insilico Medicine and Tenacia Biotechnology have expanded their AI-driven CNS collaboration, adding a second discovery-stage program targeting an...
Diamyd Medical Secures Up to USD 125m in Equity Financing From US Specialist Investors
Stockholm-headquartered Diamyd Medical, a biotech company developing precision medicine therapies for type 1 diabetes, has entered into equity financing...
Elephas Biosciences Partners With University of Louisville to Study Immunotherapy Response in GI Cancers
Elephas Biosciences Corporation, a privately held Madison, Wisconsin-based company focused on live tissue immunotherapy response prediction, has entered...
MiNK Therapeutics and C-Further collaborate on PRAME-targeted iNKT cell therapy for pediatric cancers
New York-based MiNK Therapeutics, Inc. (Nasdaq: INKT) and C-Further, a London-headquartered international pediatric oncology consortium enabled by Cancer...
The AllSci Brief
Systematic R&D and deal news. Daily.